Canaccord Genuity Maintains Buy on TransMedics Group, Lowers Price Target to $94

Benzinga · 1d ago
Canaccord Genuity analyst Jason Mills maintains TransMedics Group (NASDAQ:TMDX) with a Buy and lowers the price target from $95 to $94.